TY - JOUR
T1 - The Impact of Sarcopenia and Low Muscle Attenuation on Overall Survival in Epithelial Ovarian Cancer
T2 - A Systematic Review and Meta-analysis
AU - McSharry, Veronica
AU - Mullee, Amy
AU - McCann, Lara
AU - Rogers, Ailin C.
AU - McKiernan, Mary
AU - Brennan, Donal J.
N1 - Publisher Copyright:
© 2020, Society of Surgical Oncology.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Background: Sarcopenia is defined as a progressive loss of skeletal muscle mass, strength and physical performance. Myosteatosis is an increase of intra- and intermuscular fat and can be measured radiologically by muscle attenuation. The study aim was to perform a systematic review and meta-analysis on the prognostic potential of sarcopenia and low muscle attenuation in relation to 3-year survival rates (3YSR) and 5YSR in epithelial ovarian cancer (EOC). Methods: A systematic literature search was conducted using the databases Ovid Medline, EMBASE, and Scopus, using PRISMA guidelines, from inception to 10th of May 2019. Studies evaluated the prognostic potential of sarcopenia and low muscle attenuation on 3YSR and 5YSR in EOC. Quality assessment of included studies was performed using the Methodological Index for Non-Randomised Studies criteria. Results: A comprehensive search of databases resulted in the identification of 2194 studies, resulting in 1695 citations meeting the inclusion criteria. Six studies were included for systematic review. Sarcopenia was not significantly associated with improved 3YSR (OR 1.7, 95% CI 0.8–3.5, p = 0.15) or 5YSR (OR 1.8, 95% CI 1.0–3.2, p = 0.07) in meta-analysis. Normal muscle attenuation was associated with a favourable 3YSR (OR 3.0, 95% CI 2.0–4.5, p < 0.001) and 5YSR (OR 2.3, 95% CI 1.6–3.4, p < 0.001) compared to low muscle attenuation. Conclusion: Our meta-analysis indicated normal muscle attenuation was significantly associated with improved 3YSR and 5YSR in patients with EOC. Sarcopenia was not significantly associated with 3YSR or 5YSR in patients with EOC.
AB - Background: Sarcopenia is defined as a progressive loss of skeletal muscle mass, strength and physical performance. Myosteatosis is an increase of intra- and intermuscular fat and can be measured radiologically by muscle attenuation. The study aim was to perform a systematic review and meta-analysis on the prognostic potential of sarcopenia and low muscle attenuation in relation to 3-year survival rates (3YSR) and 5YSR in epithelial ovarian cancer (EOC). Methods: A systematic literature search was conducted using the databases Ovid Medline, EMBASE, and Scopus, using PRISMA guidelines, from inception to 10th of May 2019. Studies evaluated the prognostic potential of sarcopenia and low muscle attenuation on 3YSR and 5YSR in EOC. Quality assessment of included studies was performed using the Methodological Index for Non-Randomised Studies criteria. Results: A comprehensive search of databases resulted in the identification of 2194 studies, resulting in 1695 citations meeting the inclusion criteria. Six studies were included for systematic review. Sarcopenia was not significantly associated with improved 3YSR (OR 1.7, 95% CI 0.8–3.5, p = 0.15) or 5YSR (OR 1.8, 95% CI 1.0–3.2, p = 0.07) in meta-analysis. Normal muscle attenuation was associated with a favourable 3YSR (OR 3.0, 95% CI 2.0–4.5, p < 0.001) and 5YSR (OR 2.3, 95% CI 1.6–3.4, p < 0.001) compared to low muscle attenuation. Conclusion: Our meta-analysis indicated normal muscle attenuation was significantly associated with improved 3YSR and 5YSR in patients with EOC. Sarcopenia was not significantly associated with 3YSR or 5YSR in patients with EOC.
UR - http://www.scopus.com/inward/record.url?scp=85082973186&partnerID=8YFLogxK
U2 - 10.1245/s10434-020-08382-0
DO - 10.1245/s10434-020-08382-0
M3 - Article
C2 - 32221737
AN - SCOPUS:85082973186
SN - 1068-9265
VL - 27
SP - 3553
EP - 3564
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 9
ER -
